Dilated Cardiomyopathy and Hypothyroidism with concomitant CAD - a debatable scenario

By Bilal Bin Abdullah, Mehboob M Kalburgi, Md Zoheb, Satya Srinivas
Al Ameen medical college, Karnataka, India.

Abstract – The concept of dilated cardiomyopathy with concomitant coronary artery disease and hypothyroidism is yet a matter of debate although many theories have been postulated with this regard. We report overt heart failure due to dilated cardiomyopathy in an elderly lady with significant coronary artery disease and hypothyroidism. Early suspicion, evaluation and judicious use of thyroxine with appropriate anti-ischaemic measures proved beneficial with a better prognostic outcome in this patient.

Keywords: heart failure, dilated cardiomyopathy, ischemic heart disease, hypothyroidism. CAD: coronary artery disease.

GJMR-B Classification: NLMC Code: WG 370, WG 120, WG 142,
Dilated Cardiomyopathy and Hypothyroidism with concomitant CAD - a debatable scenario

Bilal Bin Abdullah, Mehboob M Kalburgi, Md Zoheb, Satya srinivas

Abstract - The concept of dilated cardiomyopathy with concomitant coronary artery disease and hypothyroidism is yet a matter of debate although many theories have been postulated with this regard. We report overt heart failure due to dilated cardiomyopathy in an elderly lady with significant coronary artery disease and hypothyroidism. Early suspicion, evaluation and judicious use of thyroxine with appropriate anti ischaemic measures proved beneficial with a better prognostic outcome in this patient.

Keywords : heart failure, dilated cardiomyopathy, ischemic heart disease, hypothyroidism. CAD- coronary artery disease.

I. INTRODUCTION

The heart is very sensitive to alterations in serum thyroid levels. Many of the clinical manifestations of hyperthyroidism and hypothyroidism are due to the ability of thyroid hormone to alter cardiovascular hemodynamics. Thyroid hormone metabolism is altered in many patients with acute or chronic cardiac disease, as it is in patients with other non-thyroidal illnesses. Cardiac manifestations of thyroid hormones are due to dyslipidaemia, accelerated atherogenesis, reduced heart rate, contractile states of myocardium and pericardial effusion.

The prevalence and clinical importance of myocardial dysfunction in hypothyroidism are generally overlooked. Nonspecific histological abnormalities have been demonstrated repeatedly in the hearts of myxoedema patients since first reported in 1888 in report of a committee of the Chemical Society of London. The structural changes together with haemodynamic changes in heart of a hypothyroid patient termed as hypothyroid cardiomyopathy has shown a good response to thyroxine replacement.

Ischaemic cardiac events have also been implicated in causing transient thyroid dysfunction. But whether the cardiomyopathy associated with both ischemic heart disease and hypothyroidism are interrelated is still a matter of debate as significant improvement has been seen in patients treated concurrently for the two different conditions.

II. CASE REPORT

A 61 year old lady presented to the emergency department of a tertiary institution with exertional dyspnoea since 1 week with no documented medical history. On examination the patient was mildly cyanosed, pulse rate 120 beats per minute; regular rhythm, blood pressure 110/90 mmHg, respiratory rate 32cycles/min, saturation of O2 85% with elevated JVP. Cardiovascular examination showed tachycardia with gallop rhythm and bilateral basal crepitations. A clinical diagnosis of heart failure was made. All preliminary investigations were within normal range except the lipid profile which was altered with total cholesterol- 320 mg /dl, LDL cholesterol - 180 mg/dl, HDL- 40 m/|dl, TG -380 mg \dl with normal values of CPK and Troponin-I. Electrocardiogram showed sinus tachycardia with no ST changes. Chest x-ray showed cardiomegaly with pruning of upper lobar veins and peri hilar congestion. 2D Echocardiography showed global hypokinesia with an inter ventricular septal thickness of 8.1 mm, mild mitral regurgitation, no regional wall motion abnormalities, minimal pericardial effusion and an left ventricular ejection fraction (LVEF) of 27%. She was decongested with diuretics and recovered symptomatically. An emergency coronary angiography was performed, which revealed a triple vessel disease with blocks of –left anterior descending (LAD) 60 %, left circumflex (LCX) 100%, mid right coronary artery (RCA) 100%. Respecting her LVEF of 27% she was subjected to conventional treatment. A true benefit of an interventional revascularization in this patient was a dilemma at this point, hence this patient was contemplated for radio nucleotide 99m technetium (Tc) –resting myocardial perfusion study ( figure 1,2 ) which showed severe degree of resting myocardial perfusion defects in the anterior wall, inferior and lateral walls including the apex and septum, corresponding to LAD, RCA, LCX territories and minimal to moderate degree of viable myocardium, LV dilatation with evidence of systolic and diastolic dysfunction .Her above follow up pointed out to a ischemic cause of the underlying heart failure and she was promptly started on conventional oral anti ischemic measures(Aspirin 150mg, clopidogrel 75mg), ACE inhibitors(ramipril 1.25mg), statins (atorvastatin 40mg) , aldosterone antagonist (aldactazide 75mg) and eventually referred for interventional revascularization. The clinical profile of this patient termed as hypothyroid cardiomyopathy 1888 in London.
hypothyroidism to occur following an acute coronary event or acute myocardial infarction,* but the phenomena is a sub clinical state of hypothyroidism and in heart failure, patients have low serum T3 concentration and the degree is proportional to severity of heart failure as per NYHA functional classification.\textsuperscript{8} We were in a dilemma as to whether the heart failure has depressed the thyroid hormones or hypothyroidism per se is only the true cause for this cardiomyopathy. Here significant elevation of TSH more than 150 and significant reduction in T3 and T4 made the diagnosis of hypothyroid cardiomyopathy. We had initially thought of IV T3 as an immediate therapy to tide over this crisis but due to its non availability we treated this patient cautiously with thyroxine initiating with the lowest possible dose, gradually building up the dose to a maximum of 0.1 mg within 6 weeks. In fact risk versus benefits with thyroxine therapy in elderly patients with concomitant coronary artery disease were thought seriously as thyroxine is known to improve the cardiac contractility and reduce the peripheral vascular resistance and has no effect in improving the LVEF. Theories have explained maximum beneficial effects of thyroxine in patients who were diagnosed to have heart disease in long standing hypothyroidism* but in our case it was a risk as patient was tachycardic. Many of the patients with severe heart failure in hypothyroidism with significantly compromised LVEF, poor LV systolic function and a jeopardized myocardium are expected to have prolonged QT interval and abrupt initiation of thyroxine therapy in them may culminate with torsade de pointes, ventricular arrhythmias and a premature sudden cardiac death.

Whether the thyroid condition in this case was a separate preexisting entity precipitating the underlying cardiac events or whether it was precipitated by the cardiac event was yet to be explained.

IV. Conclusion

Patients with thyroid diseases often have symptoms and signs indicating changes in cardiovascular hemodynamics. Indeed, symptoms and signs referable to the cardiovascular system may be the only manifestations of thyroid dysfunction, and thyroid function should therefore be assessed by the measurement of serum thyrotropin concentrations in patients with cardiovascular disease. Patients with cardiovascular disease, like patients with other nonthyroidal illnesses, have changes in thyroid hormone metabolism that may alter cardiac function. Although some data suggest that the thyroid replacement therapy may benefit some patients with cardiovascular disease, further studies are required to establish specific treatment recommendations.

References


**FIGURES**

![Figure 1](image1)

![Figure 2](image2)
Figure 3: Serial chest radiographs of the patient (a) at the time of presentation (b, c) during follow up following onset of therapy.